150 related articles for article (PubMed ID: 17075137)
21. Abnormal glycosylation of procathepsin L due to N-terminal point mutations correlates with failure to sort to lysosomes.
Chapman RL; Kane SE; Erickson AH
J Biol Chem; 1997 Mar; 272(13):8808-16. PubMed ID: 9079717
[TBL] [Abstract][Full Text] [Related]
22. The major secreted cathepsin L1 protease of the liver fluke, Fasciola hepatica: a Leu-12 to Pro-12 replacement in the nonconserved C-terminal region of the prosegment prevents complete enzyme autoactivation and allows definition of the molecular events in prosegment removal.
Stack CM; Donnelly S; Lowther J; Xu W; Collins PR; Brinen LS; Dalton JP
J Biol Chem; 2007 Jun; 282(22):16532-43. PubMed ID: 17403677
[TBL] [Abstract][Full Text] [Related]
23. The prosequence of procaricain forms an alpha-helical domain that prevents access to the substrate-binding cleft.
Groves MR; Taylor MA; Scott M; Cummings NJ; Pickersgill RW; Jenkins JA
Structure; 1996 Oct; 4(10):1193-203. PubMed ID: 8939744
[TBL] [Abstract][Full Text] [Related]
24. Crystal structure and inhibition studies of transglutaminase from Streptomyces mobaraense.
Yang MT; Chang CH; Wang JM; Wu TK; Wang YK; Chang CY; Li TT
J Biol Chem; 2011 Mar; 286(9):7301-7. PubMed ID: 21193394
[TBL] [Abstract][Full Text] [Related]
25. Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases.
Carmona E; Dufour E; Plouffe C; Takebe S; Mason P; Mort JS; Ménard R
Biochemistry; 1996 Jun; 35(25):8149-57. PubMed ID: 8679567
[TBL] [Abstract][Full Text] [Related]
26. Sorting of non-glycosylated human procathepsin S in mammalian cells.
Nissler K; Kreusch S; Rommerskirch W; Strubel W; Weber E; Wiederanders B
Biol Chem; 1998 Feb; 379(2):219-24. PubMed ID: 9524075
[TBL] [Abstract][Full Text] [Related]
27. Crystal structures of human procathepsin H.
Hao Y; Purtha W; Cortesio C; Rui H; Gu Y; Chen H; Sickmier EA; Manzanillo P; Huang X
PLoS One; 2018; 13(7):e0200374. PubMed ID: 30044821
[TBL] [Abstract][Full Text] [Related]
28. Structure of a Cys25-->Ser mutant of human cathepsin S.
Turkenburg JP; Lamers MB; Brzozowski AM; Wright LM; Hubbard RE; Sturt SL; Williams DH
Acta Crystallogr D Biol Crystallogr; 2002 Mar; 58(Pt 3):451-5. PubMed ID: 11856830
[TBL] [Abstract][Full Text] [Related]
29. Full-length cDNA of human cathepsin F predicts the presence of a cystatin domain at the N-terminus of the cysteine protease zymogen.
Nägler DK; Sulea T; Ménard R
Biochem Biophys Res Commun; 1999 Apr; 257(2):313-8. PubMed ID: 10198209
[TBL] [Abstract][Full Text] [Related]
30. Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides.
Chowdhury SF; Sivaraman J; Wang J; Devanathan G; Lachance P; Qi H; Ménard R; Lefebvre J; Konishi Y; Cygler M; Sulea T; Purisima EO
J Med Chem; 2002 Nov; 45(24):5321-9. PubMed ID: 12431059
[TBL] [Abstract][Full Text] [Related]
31. The occluding loop in cathepsin B defines the pH dependence of inhibition by its propeptide.
Quraishi O; Nägler DK; Fox T; Sivaraman J; Cygler M; Mort JS; Storer AC
Biochemistry; 1999 Apr; 38(16):5017-23. PubMed ID: 10213604
[TBL] [Abstract][Full Text] [Related]
32. Crystal structure of human cathepsin S.
McGrath ME; Palmer JT; Brömme D; Somoza JR
Protein Sci; 1998 Jun; 7(6):1294-302. PubMed ID: 9655332
[TBL] [Abstract][Full Text] [Related]
33. Cytochemical demonstration of expression and distribution of non-glycosylated human lysosomal cathepsin S in HEK 293 cells.
Nissler K; Oehring H; Krieg R; Pierskalla A; Weber E; Wiederanders B; Halbhuber KJ
Cell Mol Biol (Noisy-le-grand); 2002; 48 Online Pub():OL297-308. PubMed ID: 12643447
[TBL] [Abstract][Full Text] [Related]
34. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase.
Elkins PA; Ho YS; Smith WW; Janson CA; D'Alessio KJ; McQueney MS; Cummings MD; Romanic AM
Acta Crystallogr D Biol Crystallogr; 2002 Jul; 58(Pt 7):1182-92. PubMed ID: 12077439
[TBL] [Abstract][Full Text] [Related]
35. Glycosaminoglycans facilitate procathepsin B activation through disruption of propeptide-mature enzyme interactions.
Caglic D; Pungercar JR; Pejler G; Turk V; Turk B
J Biol Chem; 2007 Nov; 282(45):33076-85. PubMed ID: 17726009
[TBL] [Abstract][Full Text] [Related]
36. Comparing sequence and structure of falcipains and human homologs at prodomain and catalytic active site for malarial peptide based inhibitor design.
Musyoka TM; Njuguna JN; Tastan Bishop Ö
Malar J; 2019 May; 18(1):159. PubMed ID: 31053072
[TBL] [Abstract][Full Text] [Related]
37. Crystallization and preliminary X-ray diffraction studies of human procathepsin L.
Coulombe R; Li Y; Takebe S; Ménard R; Mason P; Mort JS; Cygler M
Proteins; 1996 Jul; 25(3):398-400. PubMed ID: 8844874
[TBL] [Abstract][Full Text] [Related]
38. Carboxy-monopeptidase substrate specificity of human cathepsin X.
Devanathan G; Turnbull JL; Ziomek E; Purisima EO; Ménard R; Sulea T
Biochem Biophys Res Commun; 2005 Apr; 329(2):445-52. PubMed ID: 15737607
[TBL] [Abstract][Full Text] [Related]
39. Folding and activation of human procathepsin S from inclusion bodies produced in Escherichia coli.
Kopitar G; Dolinar M; Strukelj B; Pungercar J; Turk V
Eur J Biochem; 1996 Mar; 236(2):558-62. PubMed ID: 8612629
[TBL] [Abstract][Full Text] [Related]
40. Selectivity of propeptide-enzyme interaction in cathepsin L-like cysteine proteases.
Schilling K; Körner A; Sehmisch S; Kreusch A; Kleint R; Benedix Y; Schlabrakowski A; Wiederanders B
Biol Chem; 2009 Feb; 390(2):167-74. PubMed ID: 19040358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
